

For Immediate Release

MEDX HEALTH CORP.

NEWS RELEASE

TSX Venture Symbol: MDX

CUSIP #: 585090

MEDX HEALTH CORP. ENTERS INTO ADVISORY AGREEMENT WITH BYRON CAPITAL MARKETS

December 5, 2012 - Ontario, Canada: MedX Health Corp. (“MDX” or the “Company”, TSX – MDX) announces that it has entered into an advisory agreement (the “Agreement”) with Byron Capital Markets Ltd. (“Byron”).

Byron will, over a two month period commencing on the date of signature of the Agreement, facilitate MDX’s access to capital markets and identify potential acquisition, divestiture or merger opportunities. In addition, Byron will provide strategic advice to MDX with the intent to maximize shareholder value, assist with introduction to potential strategic investors, and assist MDX in structuring future transactions.

MDX will pay Byron a total fee of \$200,000, payable as to \$100,000 in cash and \$100,000 in common shares of the Corporation (the “Shares”). The issue price of the Shares will be calculated pursuant to the policies of the TSX Venture Exchange, and will be subject to all relevant regulatory and other consents and approvals.

MedX Health Corp. (“MedX” or “the Company”) was incorporated on April 15, 1999 under the laws of Ontario. MedX has recently completed development of its Siascopy line of products. The Siascope is a patented optical biopsy technology used in early diagnosis of skin cancer. The Siascopy products will be launched under the trademarked names “MoleMate” and “SIMSYS”. All the Siascopy products are US Food and Drug Administration approved, and Health Canada cleared and are produced in an ISO 13485:2003 certified manufacturing and testing facility.

MedX is a global leader in the development, manufacture and distribution of quality low level laser light technology and light imaging systems, for use in numerous medical settings for tissue repair including rehab/sports medicine, dentistry, wound care, aesthetics, pain management, and imaging of suspicious moles or lesions.

MedX products offer effective treatment through a powerful and proven modality – giving patients a rapid, drug-free and non-invasive healing solution. MedX laser and light products are used by practitioners in clinics, academic facilities, and hospitals as well as by professional athletes and sports teams to improve quality of life through accelerating healing and reducing pain. MedX brand products are US Food and Drug Administration approved, CE mark approved and Health Canada cleared and are produced in an ISO 13485:2003 certified manufacturing and testing facility.

For further information, please contact Louie Canitano, Executive VP, Operations at (905) 670-4428 Email inquiries should be made to canitano@medxhealth.com and the company website is located at www.medxhealth.com. Inquiries by direct mail should be addressed to; MedX Health 220 Superior Blvd., Mississauga, Ontario, L5T 2L2

Byron Capital Markets Ltd.

Byron Capital Markets Ltd.'s current operations were founded in 2009 by a group of experienced entrepreneurs looking to build an innovative, intellectually-driven and independent investment dealer focused on providing an unparalleled level of service to institutional investors and to corporate clients throughout the lifecycle of their businesses. Today, Byron serves clients in Canada and from around the world including Europe and Australia and is on the fast track to building a global clientele.

The Byron team brings a unique set of skills, insights and experience to numerous sectors of the global economy including metals and mining, oil and gas, alternative energy, technology, healthcare, life sciences and special situations.

Byron is wholly-owned by its employees, many of whom have had extensive experience in the securities industry, the field of accounting, the practice of law and industry experience in a wide range of disciplines. This combination of experience and ownership cultivates an environment supported by industry acumen and driven by directly motivated entrepreneurs.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Certain information set out in this News Release constitutes forward-looking information. Forward-looking statements (often, but not always, identified by the use of words such as "expect", "may", "could", "anticipate" or "will" and similar expressions) may describe expectations, opinions or guidance that are not statements of fact and which may be based upon information provided by third parties. Forward-looking statements are based upon the opinions, expectations and estimates of management of MDX as at the date the statements are made and are subject to a variety of known and unknown risks and uncertainties and other factors that could cause actual events or outcomes to differ materially from those anticipated or implied by such forward-looking statements. Although MDX believes that the expectations reflected in the forward-looking statements set out in this press release or incorporated herein by reference are reasonable, it can give no assurance that such expectations will prove to have been correct. The forward-looking statements of MDX contained in this News Release, or incorporated herein by reference, are expressly qualified, in their entirety, by this cautionary statement and the risk factors contained in MDX's current annual information form available at www.sedar.com.